# US 2026/0158108 A1 · Modified mrna therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0158108 A1
- Document ID: US20260158108A1
- Status: Published application
- Kind: A1
- Application number: 18/706,085
- Filed: 2022-11-01
- Published: 2026-06-11
- Earliest claimed: 2021-11-01
- Assignees: Shattuck Labs, Inc.
- Applicants: Shattuck Labs, Inc.
- Inventors: Taylor SCHREIBER; George FROMM; Casey SHUPTRINE
- Web page: https://patentgrep.com/patent/US20260158108A1

## CPC

- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 31/60: Salicylic acid; Derivatives thereof
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61K 31/618: having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/178: {Lectin superfamily, e.g. selectins}
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/7056: {Lectin superfamily, e.g. CD23, CD72}
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 16/244: {Interleukins [IL]}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to, inter alia, compositions and methods for nucleic acid-based delivery of chimeric proteins that find use in the treatment of a disease or disorder such as selected from cancer, autoimmunity, fibrotic disease, and other inflammatory disorders.

## Claims

### Claim 1

A method for treating a cancer, an autoimmune condition, or an inflammatory disorder subject comprising a step of administering to the subject a pharmaceutical composition comprising an isolated polynucleotide encoding a chimeric protein having a general structure of:
wherein:
(a) is a first domain comprising an extracellular domain of T cell immunoreceptor with Ig and ITIM domains (TIGIT), or a variant or a fragment thereof that is capable of binding a TIGIT ligand,
(c) is a second domain comprising an extracellular domain of glucocorticoid-induced TNFR-related protein ligand (GITRL), or a variant or a fragment thereof that is capable of binding a GITRL receptor, or LIGHT (homologous to lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes), or a variant or a fragment thereof that is capable of binding a LIGHT receptor,
(b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge-CH2-CH3 Fc domain.

### Claim 2 (depends on 1)

The method of claim 1, wherein the TIGIT ligand is selected from CD155/PVR, Nectin-2, Nectin-3 and Nectin-4.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the GITRL receptor is glucocorticoid-induced TNFR-related protein (GITR).

### Claim 4 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the LIGHT receptor is TNFRSF3/LTBR.

### Claim 5

A method for treating a cancer, an autoimmune condition, or an inflammatory disorder subject comprising a step of administering to the subject a pharmaceutical composition comprising an isolated polynucleotide encoding a chimeric protein having a general structure of:
wherein:
(a) is a first domain comprising an extracellular domain of programmed death-1 (PD-1), or a variant or a fragment thereof that capable of binding a PD-1 ligand,
(c) is a second domain comprising an extracellular domain of OX40 ligand (OX40L), or a variant or a fragment thereof that capable of binding an OX40L receptor, or 4-1BB Ligand (4-1BBL), or a variant or a fragment thereof that capable of binding a 4-1BBL receptor,
(b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge-CH2-CH3 Fc domain.

### Claim 6 (depends on 5)

The method of claim 5, wherein the PD-1 ligand is PD-L1 or PD-L2.

### Claim 7 (depends on 5, 6)

The method of claim 5 or claim 6, wherein the OX40L receptor is OX40.

### Claim 8 (depends on 5, 6)

The method of claim 5 or claim 6, wherein the 4-1BBL receptor is 4-1BB.

### Claim 9

A method for treating a cancer, an autoimmune condition, or an inflammatory disorder subject comprising a step of administering to the subject a pharmaceutical composition comprising an isolated polynucleotide encoding a chimeric protein having a general structure of:
wherein:
(a) is a first domain comprising an extracellular domain of T-cell immunoglobulin mucin receptor 3 (TIM3), or a variant or a fragment thereof that capable of binding a TIM3 ligand,
(c) is a second domain comprising an extracellular domain of CD40 ligand (CD40L), or a variant or a fragment thereof that capable of binding a CD40L receptor,
(b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge-CH2-CH3 Fc domain.

### Claim 10 (depends on 9)

The method of claim 9, wherein the TIM3 ligand is selected from galectin 9, phosphatidylserine (PtdSer), CEACAM1 and high mobility group protein B1 (HMGB1).

### Claim 11 (depends on 9, 10)

The method of claim 9 or claim 10, wherein the CD40L receptor is CD40.

### Claim 12

A method for treating a cancer, an autoimmune condition, or an inflammatory disorder subject comprising a step of administering to the subject a pharmaceutical composition comprising an isolated polynucleotide encoding a chimeric protein having a general structure of:
wherein:
(a) is a first domain comprising an extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8), or a variant or a fragment thereof that capable of binding a VSIG8 ligand,
(c) is a second domain comprising an extracellular domain of 4-1BB Ligand (4-1BBL), or a variant or a fragment thereof that capable of binding a 4-1BBL receptor,
(b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge-CH2-CH3 Fc domain.

### Claim 13 (depends on 12)

The method of claim 12, wherein the 4-1BBL receptor is 4-1BB.

### Claim 14

A method for treating a cancer, an autoimmune condition, or an inflammatory disorder subject comprising a step of administering to the subject a pharmaceutical composition comprising an isolated polynucleotide encoding a chimeric protein having a general structure of:
wherein:
(a) is a first domain comprising an extracellular domain of signal regulatory protein a (SIRPα), or a variant or a fragment thereof that is capable of binding a SIRPα ligand,
(c) is a second domain comprising an extracellular domain of CD40 ligand (CD40L), or a variant or a fragment thereof that is capable of binding a CD40L receptor,
(b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge-CH2-CH3 Fc domain.

### Claim 15 (depends on 14)

The method of claim 14, wherein the SIRPα ligand is CD47.

### Claim 16 (depends on 14)

The method of claim 14, wherein the CD40L receptor is CD40.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1 to 16, wherein the hinge-CH2-CH3 Fc domain is derived from IgG1, optionally human IgG1.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1 to 17, wherein the linker comprises the hinge-CH2-CH3 Fc domain is derived from IgG4, optionally human IgG4.

### Claim 19 (depends on 17, 18)

The method of claim 17 or claim 18, wherein the hinge-CH2-CH3 Fc domain comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1 to 19, wherein the linker further comprises wherein the linker further comprises the linker comprises one or more joining linkers, such joining linkers independently selected from SEQ ID NOs: 6 to 52, optionally wherein the linker comprises two or more joining linkers each joining linker independently selected from SEQ ID NOs: 6 to 52; wherein one joining linker is N terminal to the hinge-CH2-CH3-Fc domain and another joining linker is C terminal to the hinge-CH2-CH3-Fc domain.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1 to 20, wherein the polynucleotide is or comprises an mRNA or a modified mRNA (mmRNA).

### Claim 22 (depends on 21)

The method of claim 21, wherein the polynucleotide is or comprises an mmRNA.

### Claim 23 (depends on 22)

The method of claim 22, wherein the mmRNA further comprises a 3′ untranslated region (UTR).

### Claim 24 (depends on 23)

The method of claim 23, wherein the 3′ UTR comprises at least one microRNA-122 (miR-122) binding site.

### Claim 25 (depends on 24)

The method of claim 24, wherein the miR-122 binding site is a miR-122-3p binding site or a miR-122-5-binding site.

### Claim 26 (depends on 24, 25)

The method of claim 24 or claim 25, wherein the mmRNA further comprises a spacer sequence between the open reading frame and the miRNA binding site.

### Claim 27 (depends on 26)

The method of claim 26, wherein the spacer sequence comprises at least about 10 nucleotides, at least about 20 nucleotides, at least about 30 nucleotides, at least about 40 nucleotides, at least about 50 nucleotides, at least about 60 nucleotides, at least about 70 nucleotides, at least about 80 nucleotides, at least about 90 nucleotides, or at least about 100 nucleotides.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 21-27, wherein the mmRNA further comprises a 5′ UTR.

### Claim 29 (depends on 28)

The method of claim 28, wherein the 5′ UTR harbors a Kozak sequence and/or forms a secondary structure that stimulate elongation factor binding.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 21-29, wherein the mmRNA further comprises a 5′ terminal cap.

### Claim 31 (depends on 30)

The method of claim 30, wherein the 5′ terminal cap is a Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2′fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azidoguanosine, Cap2, Cap4, 5′ methylG cap, or an analog thereof.

### Claim 32 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 21-31, wherein the mmRNA comprises one or more modifications.

### Claim 33 (depends on 32)

The method of claim 32, wherein the modifications are selected from:
pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, pseudouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2, 6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine, and a combination of any two or more thereof; and/or
wherein the modifications are selected from pseudouridine (Ψ), N1-methylpseudouridine (m1Ψ), 2-thiouridine (s2U), 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methoxyuridine, 2′-O-methyl uridine, 1-methyl-pseudouridine (m1L), 5-methoxy-uridine (mo5U), 5-methyl-cytidine (m5C), α-thio-guanosine, α-thio-adenosine, 5-cyano uridine, 4′-thio uridine 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenosine (m6A), and 2,6-Diaminopurine, (I), 1-methylinosine (m1I), wyosine (imG), methylwyosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, and a combination of any two or more thereof.

### Claim 34 (depends on 31, 32)

The method of any one of claim 31 or 32, wherein modification is selected from pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and a combination thereof.

### Claim 35 (depends on 31, 32, 33, 34)

The method of any one of claims 31 to 34, wherein the mmRNA comprises at least one N1-methylpseudouridine.

### Claim 36 (depends on 31, 32, 33, 34, 35)

The method of any one of claims 31 to 35, wherein the mmRNA is fully modified with chemically-modified uridines.

### Claim 37 (depends on 36)

The method of claim 36, wherein the mmRNA is a fully modified with N1-methylpseudouridine.

### Claim 38 (depends on 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 31 to 37, wherein the modifications are selected from pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, pseudouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, and 4-methoxy-2-thio-pseudouridine or a combination of any two or more thereof.

### Claim 39 (depends on 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 31 to 38, wherein the modifications are selected from 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, and 4-methoxy-1-methyl-pseudoisocytidine.

### Claim 40 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 31 to 39, wherein the modifications are selected from 2-aminopurine, 2, 6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine.

### Claim 41 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 31 to 40, wherein the modifications are selected from inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine.

### Claim 42 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 31 to 41, wherein the modifications are present on the major groove face.

### Claim 43 (depends on 42)

The method of claim 42, wherein a hydrogen on C-5 of uracil is replaced with a methyl group or a halo group.

### Claim 44 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 31 to 43, wherein the mmRNA further comprises one or more modifications selected from 5′-O-(1-Thiophosphate)-Adenosine, 5′-O-(1-Thiophosphate)-Cytidine, 5′-O-(1-Thiophosphate)-Guanosine, 5′-O-(1-Thiophosphate)-Uridine and 5′-O-(1-Thiophosphate)-Pseudouridine.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1 to 44, wherein the pharmaceutical composition further comprises a lipidoid, a liposome, a lipoplex, a lipid nanoparticle, a polymeric nanoparticle, a peptide, a protein, a cell, a nanoparticle mimic, a nanotube, or a conjugate.

### Claim 46 (depends on 45)

The method of claim 45, wherein the pharmaceutical composition is formulated as a lipid nanoparticle (LNP), a lipoplex, or a liposome.

### Claim 47 (depends on 46)

The method of claim 46, wherein the pharmaceutical composition is formulated as a lipid nanoparticle (LNP).

### Claim 48 (depends on 47)

The method of claim 47, wherein the LNP comprises a molar ratio of about 20-60% ionizable amino lipid, about 5-25% phospholipid, about 25-55% structural lipid, and about 0.5-1.5% PEG lipid.

### Claim 49 (depends on 47, 48)

The method of claim 47 or claim 48, wherein the LNP comprises a molar ratio of about 50% ionizable amino lipid, about 8-12% phospholipid, about 37-40% structural lipid, and about 1-2% PEG lipid.

### Claim 50 (depends on 47, 48, 49)

The method of any one of claims 47 to 49, wherein the lipid nanoparticles comprise lipids selected from an ionizable lipid (e.g., an ionizable cationic lipid selected from DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5, and C12-200); a structural lipid (e.g., distearoylphosphatidylcholine (DSPC)); cholesterol, and a polyethyleneglycol (PEG)-lipid (e.g., a PEG-diacylglycerol (DAG), a PEG-dialkyloxypropyl (DAA), a PEG-phospholipid, a PEG-ceramide (Cer), or a mixture thereof, or a PEG-dilauryloxypropyl (C12, a PEG-dimyristyloxypropyl (C14), a PEG-dipalmityloxypropyl (C16), or a PEG-distearyloxypropyl (C18)); 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP); dioleoylphosphatidylethanolamine (DOPE).

### Claim 51 (depends on 47, 48, 49, 50)

The method of any one of claims 47 to 50, wherein the lipid nanoparticles comprise (a) a cationic lipid comprising from 50 mol % to 85 mol % of the total lipid present in the particle; (b) a non-cationic lipid comprising from 13 mol % to 49.5 mol % of the total lipid present in the particle; and (c) a conjugated lipid that inhibits aggregation of particles comprising from 0.5 mol % to 2 mol % of the total lipid present in the particle.

### Claim 52 (depends on 47, 48, 49, 50, 51)

The method of any one of claims 47 to 51, wherein the lipid nanoparticles comprise a lipid selected from SM-102, DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5, and C12-200; a cholesterol; and a PEG-lipid.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 1 to 52, wherein the pharmaceutical composition is formulated for parenteral administration.

### Claim 54

A pharmaceutical composition comprising an isolated modified mRNA (mmRNA) encoding a heterologous chimeric protein having an amino acid sequence that has at least about 95% sequence identity with an amino acid sequence selected from SEQ ID NOs: 80, 81, and 90-93.

### Claim 55 (depends on 54)

The pharmaceutical composition of claim 54, wherein the mmRNA comprises a 3′ untranslated region (UTR).

### Claim 56 (depends on 55)

The pharmaceutical composition of claim 55, wherein the 3′ UTR comprises at least one microRNA-122 (miR-122) binding site, optionally wherein the miR-122 binding site is a miR-122-3p binding site or a miR-122-5-binding site.

### Claim 57 (depends on 54, 55, 56)

The pharmaceutical composition of any one of claims 54 to 56, wherein the mmRNA further comprises a spacer sequence between the open reading frame and the miRNA binding site, optionally wherein the spacer sequence comprises at least about 10 nucleotides, at least about 20 nucleotides, at least about 30 nucleotides, at least about 40 nucleotides, at least about 50 nucleotides, at least about 60 nucleotides, at least about 70 nucleotides, at least about 80 nucleotides, at least about 90 nucleotides, or at least about 100 nucleotides.

### Claim 58 (depends on 54, 55, 56, 57)

The pharmaceutical composition of any one of claims 54-57, wherein the mmRNA further comprises a 5′ UTR, optionally wherein the 5′ UTR harbors a Kozak sequence and/or forms a secondary structure that stimulate elongation factor binding.

### Claim 59 (depends on 54, 55, 56, 57, 58)

The pharmaceutical composition of any one of claims 54-58, wherein the mmRNA further comprises a 5′ terminal cap.

### Claim 60 (depends on 59)

The pharmaceutical composition of claim 59, wherein the 5′ terminal cap is a Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2′fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azidoguanosine, Cap2, Cap4, 5′ methylG cap, or an analog thereof.

### Claim 61 (depends on 54, 55, 56, 57, 58, 59, 60)

The pharmaceutical composition of any one of claims 54-60, wherein the mmRNA comprises one or more modifications.

### Claim 62 (depends on 61)

The pharmaceutical composition of claim 61, wherein the modifications are selected from pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, pseudouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2, 6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine, and a combination of any two or more thereof.

### Claim 63 (depends on 61, 62)

The pharmaceutical composition of claim 61 or claim 62, wherein the modifications are selected from pseudouridine (Ψ), N1-methylpseudouridine (m1Ψ), 2-thiouridine (s2U), 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methoxyuridine, 2′-O-methyl uridine, 1-methyl-pseudouridine (m1Ψ), 5-methoxy-uridine (mo5U), 5-methyl-cytidine (m5C), α-thio-guanosine, α-thio-adenosine, 5-cyano uridine, 4′-thio uridine 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenosine (m6A), and 2,6-Diaminopurine, (I), 1-methylinosine (m1I), wyosine (imG), methylwyosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, and a combination of any two or more thereof.

### Claim 64 (depends on 61, 62, 63)

The pharmaceutical composition of any one of claims 61 to 63, wherein modification is selected from pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and a combination thereof.

### Claim 65 (depends on 61, 62, 63, 64)

The pharmaceutical composition of any one of claims 61 to 64, wherein the mmRNA comprises at least one N1-methylpseudouridine.

### Claim 66 (depends on 61, 62, 63, 64, 65)

The pharmaceutical composition of any one of claims 61 to 65, wherein the mmRNA is fully modified with chemically-modified uridines.

### Claim 67 (depends on 66)

The pharmaceutical composition of claim 66, wherein the mmRNA is a fully modified with N1-methylpseudouridine.

### Claim 68 (depends on 61, 62, 63, 64, 65, 66, 67)

The pharmaceutical composition of any one of claims 61 to 67, wherein the modifications are selected from pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, pseudouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, and 4-methoxy-2-thio-pseudouridine or a combination of any two or more thereof.

### Claim 69 (depends on 61, 62, 63, 64, 65, 66, 67, 68)

The pharmaceutical composition of any one of claims 61 to 68, wherein the modifications are selected from 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, and 4-methoxy-1-methyl-pseudoisocytidine.

### Claim 70 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69)

The pharmaceutical composition of any one of claims 61 to 69, wherein the modifications are selected from 2-aminopurine, 2, 6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine.

### Claim 71 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The pharmaceutical composition of any one of claims 61 to 70, wherein the modifications are selected from inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine.

### Claim 72 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The pharmaceutical composition of any one of claims 61 to 71, wherein the modifications are present on the major groove face.

### Claim 73 (depends on 72)

The pharmaceutical composition of claim 72, wherein a hydrogen on C-5 of uracil is replaced with a methyl group or a halo group.

### Claim 74 (depends on 71, 72, 73)

The pharmaceutical composition of any one of claims 71 to 73, wherein the mmRNA further comprises one or more modifications selected from 5′-O-(1-Thiophosphate)-Adenosine, 5′-O-(1-Thiophosphate)-Cytidine, 5′-O-(1-Thiophosphate)-Guanosine, 5′-O-(1-Thiophosphate)-Uridine and 5′-O-(1-Thiophosphate)-Pseudouridine.

### Claim 75 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The pharmaceutical composition of any one of claims 54 to 74, wherein the pharmaceutical composition further comprises a lipidoid, a liposome, a lipoplex, a lipid nanoparticle, a polymeric nanoparticle, a peptide, a protein, a cell, a nanoparticle mimic, a nanotube, or a conjugate.

### Claim 76 (depends on 75)

The pharmaceutical composition of claim 75, wherein the pharmaceutical composition is formulated as a lipid nanoparticle (LNP), a lipoplex, or a liposome.

### Claim 77 (depends on 76)

The pharmaceutical composition of claim 76, wherein the pharmaceutical composition is formulated as a lipid nanoparticle (LNP).

### Claim 78 (depends on 77)

The pharmaceutical composition of claim 77, wherein the LNP comprises a molar ratio of about 20-60% ionizable amino lipid, about 5-25% phospholipid, about 25-55% structural lipid, and about 0.5-1.5% PEG lipid.

### Claim 79 (depends on 77, 78)

The pharmaceutical composition of claim 77 or claim 78, wherein the LNP comprises a molar ratio of about 50% ionizable amino lipid, about 8-12% phospholipid, about 37-40% structural lipid, and about 1-2% PEG lipid.

### Claim 80 (depends on 77, 78, 79)

The pharmaceutical composition of any one of claims 77 to 79, wherein the lipid nanoparticles comprise lipids selected from an ionizable lipid (e.g., an ionizable cationic lipid selected from DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5, and C12-200); a structural lipid (e.g., distearoylphosphatidylcholine (DSPC)); cholesterol, and a polyethyleneglycol (PEG)-lipid (e.g., a PEG-diacylglycerol (DAG), a PEG-dialkyloxypropyl (DAA), a PEG-phospholipid, a PEG-ceramide (Cer), or a mixture thereof, or a PEG-dilauryloxypropyl (C12, a PEG-dimyristyloxypropyl (C14), a PEG-dipalmityloxypropyl (C16), or a PEG-distearyloxypropyl (C18)); 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP); dioleoylphosphatidylethanolamine (DOPE).

### Claim 81 (depends on 77, 78, 79, 80)

The pharmaceutical composition of any one of claims 77 to 80, wherein the lipid nanoparticles comprise (a) a cationic lipid comprising from 50 mol % to 85 mol % of the total lipid present in the particle; (b) a non-cationic lipid comprising from 13 mol % to 49.5 mol % of the total lipid present in the particle; and (c) a conjugated lipid that inhibits aggregation of particles comprising from 0.5 mol % to 2 mol % of the total lipid present in the particle.

### Claim 82 (depends on 77, 78, 79, 80, 81)

The pharmaceutical composition of any one of claims 77 to 81, wherein the lipid nanoparticles comprise a lipid selected from SM-102, DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5, and C12-200; a cholesterol; and a PEG-lipid.

### Claim 83 (depends on 77, 78, 79, 80, 81, 82)

The pharmaceutical composition of any one of claims 77 to 82, wherein the heterologous chimeric protein has an amino acid sequence that has at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity with an amino acid sequence selected from SEQ ID NOs: 80, 81, and 90-93.

### Claim 84

A pharmaceutical composition comprising an isolated modified mRNA (mmRNA) encoding a heterologous chimeric protein having an amino acid sequence that has at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity with an amino acid sequence selected from SEQ ID NOs: 80, 81, and 90-93.

### Claim 85 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The pharmaceutical composition of any one of claims 54 to 81, wherein the pharmaceutical composition is formulated for parenteral administration.

### Claim 86 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

A method for treating a cancer, an autoimmune condition, or an inflammatory disorder subject comprising a step of administering to the subject the pharmaceutical composition of any one of claims 54 to 82.
